FRM
Fox Run Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $412K | Buy |
+1,263
| New | +$412K | 0.07% | 543 |
|
|
2025
Q1 | – | Sell |
-2,809
| Closed | -$661K | – | 889 |
|
|
2024
Q4 | $661K | Sell |
2,809
-76
| -3% | -$17.9K | 0.12% | 342 |
|
|
2024
Q3 | $793K | Buy |
+2,885
| New | +$793K | 0.18% | 195 |
|
|
2024
Q2 | – | Sell |
-2,988
| Closed | -$447K | – | 757 |
|
|
2024
Q1 | $447K | Buy |
2,988
+1,532
| +105% | +$229K | 0.1% | 408 |
|
|
2023
Q4 | $279K | Buy |
+1,456
| New | +$279K | 0.07% | 521 |
|
|
2023
Q3 | – | Sell |
-2,797
| Closed | -$531K | – | 688 |
|
|
2023
Q2 | $531K | Buy |
+2,797
| New | +$531K | 0.15% | 268 |
|
|
2021
Q3 | – | Sell |
-1,947
| Closed | -$330K | – | 452 |
|
|
2021
Q2 | $330K | Buy |
+1,947
| New | +$330K | 0.3% | 140 |
|
|
2019
Q3 | – | Sell |
-9,514
| Closed | -$690K | – | 347 |
|
|
2019
Q2 | $690K | Buy |
+9,514
| New | +$690K | 0.46% | 21 |
|
|
2018
Q3 | – | Sell |
-9,836
| Closed | -$969K | – | 555 |
|
|
2018
Q2 | $969K | Buy |
+9,836
| New | +$969K | 0.31% | 37 |
|
|
2018
Q1 | – | Sell |
-2,800
| Closed | -$356K | – | 698 |
|
|
2017
Q4 | $356K | Sell |
2,800
-1,800
| -39% | -$229K | 0.1% | 404 |
|
|
2017
Q3 | $540K | Buy |
+4,600
| New | +$540K | 0.15% | 261 |
|
|
2017
Q1 | – | Sell |
-6,900
| Closed | -$258K | – | 554 |
|
|
2016
Q4 | $258K | Sell |
6,900
-800
| -10% | -$29.9K | 0.14% | 350 |
|
|
2016
Q3 | $522K | Buy |
+7,700
| New | +$522K | 0.31% | 89 |
|